passion for excellence - enseval€¦ · company update unaudited ytd 31 march 2011 results passion...
TRANSCRIPT
6/30/2011
1
PT ENSEVAL PUTERA MEGATRADING TBK
COMPANY UPDATE Unaudited YTD 31 March 2011 Results
Passion For Excellence
Table of ContentsTable of Contents
I. Enseval In Brief
II. Business Overview
III. Operational Highlights
IV. Financial Highlights
6/30/2011
2
I. Enseval In Brief
Sustainable Growth
1973:PT Ensevalestablished in Oct 1973
19731973 19931993
1993 :Trading & distribution activities transferred to subsidiary, Arya Gupta Cempaka, later known as PT EPM
19941994
1994: The Company was listed on Indonesian Stock Exchange
20032003
2003: Incorporation of Subsidiary PT Milenia Dharma Insani
20072007
2007: Incorporation of Subsidiaries PT EnsevalMedika Prima & PT Global Chemindo Megatrading
20082008
2008: Incorporation of Subsidiaries PT RenalmedTiara Utama
Milestones
-
2,000
4,000
6,000
8,000
10,000
12,000
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
Net Sales
(100)
(50)
-
50
100
150
200
250
300
350
Laba (Rugi) Bersih
* Figure in IDR Billion
6/30/2011
3
• Largest Pharmaceutical distribution company in Indonesia with 42 full-service branches, 2 Regional Distribution Company and 23 branches under subsidiary & employs more than 5.000 employees
Market Leading Position in Indonesia
• Distributes more than 10 well known OTC products, nutrition products, infant milk, energy drinks and Ethical Products
Strong Product Portfolio & Diversification
• Public listed company with professional management that ensure fairness treatment to all Principals & all stakeholders
Good Corporate Governance
• Strong Net Sales growth with CAGR 12.6% from year 2005-2009 • Robust balance sheet figures
Strong Financial Track Record
• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)• Commitment to always increase market coverage and to invest and own directly all its assets, land, building, IT infrastructure, and transportation armada to serve better
Enseval’s Commitment Towards Improvement
Enseval In Brief
Shareholding Structure
Kalbe
84.13%
Public
16.25%
PT Enseval PuteraMegatrading
Tbk
PT Tri Sapta Jaya
99.99%
PT EnsevalMedika Prima
99.90%
PT Global ChemindoMegatrading
99.90%
PT Renalmed Tiara Utama
98.75%
PT MileniaDharma Insani
99.5%
0.5%
0.1%
0.1%
6/30/2011
4
II. Business Overview
Distribution & LogisticDistribution & Logistic
Product Range : Ethical, OTC, Consumer Products, Medical Device &Raw Material
Our service :
• Warehousing
• Inventory Management
• Freight & Transportation
• Sales & Support
• Order-taking, Billing & Collection
Largest pharmaceutical distributor In Indonesia
6/30/2011
5
Distribution & LogisticDistribution & Logistic
• Covers more than 150.000 outlets throughout Indonesia
• Cover most pharmacies & hospital
• Cover 80% of consumer & health market
• 24 hour order fulfillment & 4-5 hour order fulfillment for prescription
medicines
• 24 hour service for life saving drugs
• Offers value added services to customers
Medical DeviceMedical Device
• Product Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
• The Company offers Marketing services for medical devices through its
subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in
collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
• The Company has retained the trust & maintained good relationships with
multi-national principals
Offers Distributions & Marketing Services for Medical Devices
6/30/2011
6
Raw MaterialRaw MaterialRaw MaterialRaw Material
• Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary
• PT Global Chemindo Megatrading offers trading & marketing of raw material and has extensive network and collaboration with Multinational Companies from different countries, such as : United States, Europe, China, Japan, Korea and other countries.
Leading in Pharmaceutical Raw Materials Market
• Healthcare Services,with facilities such as: Clinic,
Pharmacy, Laboratory & Mini market
• Until 31 Maret 2011, The Company has 25 Clinics
in Jakarta and its greater areas
• Offered in 2 business models : direct investment &
collaboration / joint operation models
Healthcare ServicesHealthcare Services
New Retail Health Service : Mitrasana Clinic
6/30/2011
7
III. Operational Highlights
The largest pharmaceutical distribution network throughout the IndonesianArchipelago, with total 65 branches.
BranchesBranches
6/30/2011
8
• The Company conducted Extraordinary General Meetings of Shareholders on March 2nd 2011 for approval on Rights Issue I.
• The Company completed a Rights Issue I to shareholders in issuing Preemptive Rights amounting to 428,640,000 shares with a par value of Rp 50 per share, with total amount of IDR 300 Bn to finance 2 years expansion plan.
Events Highlight in 2011Events Highlight in 2011
• Infrastructures & Branches Development in branches
• Some initiatives for service quality improvement:- Enseval Customer Care (ECC) Implementation- Subdistributor Appointment to expand distribution coverage
throughout Indonesia- 24 hours Call Center Implementation, ‘After Sales Service’ &
‘Customer Service Online’ in PT Enseval Medika Prima, TheCompany’s Subsidiary
• Upgrading Oracle system to Oracle E-Business Suite Release 12 tofuther improved IT capabilities .
• The Company Subsidiary, PT Enseval Medika Prima & PT GlobalChemindo Megatrading have been known in Medical Devices & rawmaterial market in Indonesia & gained trust from MultinationalPrincipals
Operational Highlight in 2011 Operational Highlight in 2011
6/30/2011
9
Expansion Plans Expansion Plans
2 Years Expansion Plans
• Upgrade existing branches and expandwarehouse capacity to improve servicequality
• Expand distribution coverage to new areas
•Establish several RDC throughout Indonesiato ensure smooth logistics.
•Upgrade Information and technology
Human ResourcesHuman Resources
• Employs over 5,000 personnel with over 2,000 personnel are working in sales and
distribution
• The Company continues to provide training for all employees to improved its human
resources competencies
• In year 2011, The Company continues to promote CONIM Program (Continuos
Improvement) to all staffs, both in Headquarters & in all Branches.
6/30/2011
10
Principals Based on Categories
OTC Consumers Product Ethical
Major Principals Major Principals
Principals Based on Categories
Medical Devices & Diagnostic Raw Material
Friesland Foods Domo
Major Principals Major Principals
6/30/2011
11
InfrastructuresInfrastructures
More than 580
Transportation
Fleet
More than 120
Motorcycles
More than
64.000 Pallets
Size
The Usage of
Oracle System
as IT Platform
IV. Financial Highlights
6/30/2011
12
Financial Highlights Financial Highlights
Net Sales (IDR Trillion) Operating Income (IDR Billion)
Until YTD 31 March 2011, The Company recorded Net Sales of IDR 2.3 trillion, 12.3%
growth YoY, with Operating Income amounting to IDR 59,5 million
6,4
7,4
8,6
6,9
2.0 2.3
15,4%
16,1%15,7%
13,6%
10%
11%
12%
13%
14%
15%
16%
17%
0
2
4
6
8
10
12
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Sales Growth (%)
307
363
484
361
75 72
4,8%4,9%
5,7%
3,7%3.7%
3.2%
0%
1%
2%
3%
4%
5%
6%
0
100
200
300
400
500
600
2007 2008 2009 2010 Q1 2010 Q1 2011
OP OP Margin
12.3%
Financial Highlights Financial Highlights
231267 329
257
52 60
3.6%
3.6%3.9%
2.6%
2.6%2.6%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
0
50
100
150
200
250
300
350
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Income (IDR Million) Net Profit Margin
Net Income (IDR Billion)
102
117
144
113
23 26
0
20
40
60
80
100
120
140
160
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Income Per Share (IDR)
Net Income Per Share
Until YTD 31 March 2011, The Company Net Income reached IDR 59.5 million with
Net Income Per Share of IDR 26
6/30/2011
13
Sales Growth Sales Growth
759 673
348
152 94 7
2,033
882
753
417
139 83
9
2,282
Consumer
Products
Ethical OTC Raw Material Medical Device Others Consolidation
YTD 31 March 2010 YTD 31 March 2011
15%8.6%
19.7%
16.2%11.9%
10.9%
12.3%Net Sales (In IDR Billion )
Consumer
Products
38%
Ethical
33%
OTC
18%
Raw Material
6%
Medical Device
4%
Others
0%
Unaudited
YTD 31 Mar 2011
Sales ContributionSales Contribution
6/30/2011
14
2,806
388
3,194 3,141
555
3,696
Current Assets Non Current Assets Total Assets
31 March 2010 31 March 2011
15.7%
12.0%
42.9%
AssetsAssetsAssets
Figure in IDR Billion
1,504
33
1,537 1,501
36
1,537
Current Liablities Non Current Liabilities Total Liabilities
31 March 2010 31 March 2011
1,656
2,158
Equity
31 March 2010 31 March 2010
30.3%
9.0%
0.2%
Liabilities & EquityLiabilities & Equity
6/30/2011
15
Thank You For further information, please contact :
PT Enseval Putera MegatradingTbk.
EnsevalBuilding, Kawasan Industri Pulogadung
JalanPulolentut No.10
Jakarta 13920 ) Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : [email protected]
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading
Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to contain all of the
information that may be material to an investor’s decision. It should be noted that the information
contained in this Presentation is subjected to further review, and that such information may be updated
and/or amended from time to time as circumstances change or more information becomes available.
Some of those revisions or changes may be material.
Each recipient of this Presentation should therefore perform their own independent analysis of the
business, operations, financial condition, creditworthiness, status and affairs of Enseval. Each recipient
should also conduct their own enquiries into the adequacy, accuracy, and completeness of any
information relating to Enseval, as the information and data contained in this Presentation are not
substitutes for the recipient’s independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.
6/30/2011
1
PT ENSEVAL PUTERA MEGATRADING TBK
COMPANY UPDATE Unaudited YTD 31 March 2011 Results
Passion For Excellence
Table of ContentsTable of Contents
I. Enseval In Brief
II. Business Overview
III. Operational Highlights
IV. Financial Highlights
6/30/2011
2
I. Enseval In Brief
Sustainable Growth
1973:PT Ensevalestablished in Oct 1973
19731973 19931993
1993 :Trading & distribution activities transferred to subsidiary, Arya Gupta Cempaka, later known as PT EPM
19941994
1994: The Company was listed on Indonesian Stock Exchange
20032003
2003: Incorporation of Subsidiary PT Milenia Dharma Insani
20072007
2007: Incorporation of Subsidiaries PT EnsevalMedika Prima & PT Global Chemindo Megatrading
20082008
2008: Incorporation of Subsidiaries PT RenalmedTiara Utama
Milestones
-
2,000
4,000
6,000
8,000
10,000
12,000
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
Net Sales
(100)
(50)
-
50
100
150
200
250
300
350
Laba (Rugi) Bersih
* Figure in IDR Billion
6/30/2011
3
• Largest Pharmaceutical distribution company in Indonesia with 42 full-service branches, 2 Regional Distribution Company and 23 branches under subsidiary & employs more than 5.000 employees
Market Leading Position in Indonesia
• Distributes more than 10 well known OTC products, nutrition products, infant milk, energy drinks and Ethical Products
Strong Product Portfolio & Diversification
• Public listed company with professional management that ensure fairness treatment to all Principals & all stakeholders
Good Corporate Governance
• Strong Net Sales growth with CAGR 12.8% from year 2005-2010• Robust balance sheet figures
Strong Financial Track Record
• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)• Commitment to always increase market coverage and to invest and own directly all its assets, land, building, IT infrastructure, and transportation armada to serve better
Enseval’s Commitment Towards Improvement
Enseval In Brief
Shareholding Structure
Kalbe
84.13%
Public
16.25%
PT Enseval PuteraMegatrading
Tbk
PT Tri Sapta Jaya
99.99%
PT EnsevalMedika Prima
99.90%
PT Global ChemindoMegatrading
99.90%
PT Renalmed Tiara Utama
98.75%
PT MileniaDharma Insani
99.5%
0.5%
0.1%
0.1%
6/30/2011
4
II. Business Overview
Distribution & LogisticDistribution & Logistic
Product Range : Ethical, OTC, Consumer Products, Medical Device &Raw Material
Our service :
• Warehousing
• Inventory Management
• Freight & Transportation
• Sales & Support
• Order-taking, Billing & Collection
Largest pharmaceutical distributor In Indonesia
6/30/2011
5
Distribution & LogisticDistribution & Logistic
• Covers more than 150.000 outlets throughout Indonesia
• Cover most pharmacies & hospital
• Cover 80% of consumer & health market
• 24 hour order fulfillment & 4-5 hour order fulfillment for prescription
medicines
• 24 hour service for life saving drugs
• Offers value added services to customers
Medical DeviceMedical Device
• Product Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
• The Company offers Marketing services for medical devices through its
subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in
collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
• The Company has retained the trust & maintained good relationships with
multi-national principals
Offers Distributions & Marketing Services for Medical Devices
6/30/2011
6
Raw MaterialRaw MaterialRaw MaterialRaw Material
• Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary
• PT Global Chemindo Megatrading offers trading & marketing of raw material and has extensive network and collaboration with Multinational Companies from different countries, such as : United States, Europe, China, Japan, Korea and other countries.
Leading in Pharmaceutical Raw Materials Market
• Healthcare Services,with facilities such as: Clinic,
Pharmacy, Laboratory & Mini market
• Until 31 Maret 2011, The Company has 25 Clinics
in Jakarta and its greater areas
• Offered in 2 business models : direct investment &
collaboration / joint operation models
Healthcare ServicesHealthcare Services
New Retail Health Service : Mitrasana Clinic
6/30/2011
7
III. Operational Highlights
The largest pharmaceutical distribution network throughout the IndonesianArchipelago, with total 65 branches.
BranchesBranches
6/30/2011
8
• The Company conducted Extraordinary General Meetings of Shareholders on March 2nd 2011 for approval on Rights Issue I.
• The Company completed a Rights Issue I to shareholders in issuing Preemptive Rights amounting to 428,640,000 shares with a par value of Rp 50 per share, with total amount of IDR 300 Bn to finance 2 years expansion plan.
Events Highlight in 2011Events Highlight in 2011
• Infrastructures & Branches Development in branches
• Some initiatives for service quality improvement:- Enseval Customer Care (ECC) Implementation- Subdistributor Appointment to expand distribution coverage
throughout Indonesia- 24 hours Call Center Implementation, ‘After Sales Service’ &
‘Customer Service Online’ in PT Enseval Medika Prima, TheCompany’s Subsidiary
• Upgrading Oracle system to Oracle E-Business Suite Release 12 tofuther improved IT capabilities .
• The Company Subsidiary, PT Enseval Medika Prima & PT GlobalChemindo Megatrading have been known in Medical Devices & rawmaterial market in Indonesia & gained trust from MultinationalPrincipals
Operational Highlight in 2011 Operational Highlight in 2011
6/30/2011
9
Expansion Plans Expansion Plans
2 Years Expansion Plans
• Upgrade existing branches and expandwarehouse capacity to improve servicequality
• Expand distribution coverage to new areas
•Establish several RDC throughout Indonesiato ensure smooth logistics.
•Upgrade Information and technology
Human ResourcesHuman Resources
• Employs over 5,000 personnel with over 2,000 personnel are working in sales and
distribution
• The Company continues to provide training for all employees to improved its human
resources competencies
• In year 2011, The Company continues to promote CONIM Program (Continuos
Improvement) to all staffs, both in Headquarters & in all Branches.
6/30/2011
10
Principals Based on Categories
OTC Consumers Product Ethical
Major Principals Major Principals
Principals Based on Categories
Medical Devices & Diagnostic Raw Material
Friesland Foods Domo
Major Principals Major Principals
6/30/2011
11
InfrastructuresInfrastructures
More than 580
Transportation
Fleet
More than 120
Motorcycles
More than
64.000 Pallets
Size
The Usage of
Oracle System
as IT Platform
IV. Financial Highlights
6/30/2011
12
Financial Highlights Financial Highlights
Net Sales (IDR Trillion) Operating Income (IDR Billion)
Until YTD 31 March 2011, The Company recorded Net Sales of IDR 2.3 trillion, 12.3%
growth YoY, with Operating Income amounting to IDR 59,5 million
6,4
7,4
8,6
6,9
2.0 2.3
15,4%
16,1%15,7%
13,6%
10%
11%
12%
13%
14%
15%
16%
17%
0
2
4
6
8
10
12
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Sales Growth (%)
307
363
484
361
75 72
4,8%4,9%
5,7%
3,7%3.7%
3.2%
0%
1%
2%
3%
4%
5%
6%
0
100
200
300
400
500
600
2007 2008 2009 2010 Q1 2010 Q1 2011
OP OP Margin
12.3%
Financial Highlights Financial Highlights
231267 329
257
52 60
3.6%
3.6%3.9%
2.6%
2.6%2.6%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
0
50
100
150
200
250
300
350
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Income (IDR Million) Net Profit Margin
Net Income (IDR Billion)
102
117
144
113
23 26
0
20
40
60
80
100
120
140
160
2007 2008 2009 2010 Q1 2010 Q1 2011
Net Income Per Share (IDR)
Net Income Per Share
Until YTD 31 March 2011, The Company Net Income reached IDR 59.5 million with
Net Income Per Share of IDR 26
6/30/2011
13
Sales Growth Sales Growth
759 673
348
152 94 7
2,033
882
753
417
139 83
9
2,282
Consumer
Products
Ethical OTC Raw Material Medical Device Others Consolidation
YTD 31 March 2010 YTD 31 March 2011
15%8.6%
19.7%
16.2%11.9%
10.9%
12.3%Net Sales (In IDR Billion )
Consumer
Products
38%
Ethical
33%
OTC
18%
Raw Material
6%
Medical Device
4%
Others
0%
Unaudited
YTD 31 Mar 2011
Sales ContributionSales Contribution
6/30/2011
14
2,806
388
3,194 3,141
555
3,696
Current Assets Non Current Assets Total Assets
31 March 2010 31 March 2011
15.7%
12.0%
42.9%
AssetsAssetsAssets
Figure in IDR Billion
1,504
33
1,537 1,501
36
1,537
Current Liablities Non Current Liabilities Total Liabilities
31 March 2010 31 March 2011
1,656
2,158
Equity
31 March 2010 31 March 2010
30.3%
9.0%
0.2%
Liabilities & EquityLiabilities & Equity
6/30/2011
15
Thank You For further information, please contact :
PT Enseval Putera MegatradingTbk.
EnsevalBuilding, Kawasan Industri Pulogadung
JalanPulolentut No.10
Jakarta 13920 ) Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : [email protected]
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading
Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to contain all of the
information that may be material to an investor’s decision. It should be noted that the information
contained in this Presentation is subjected to further review, and that such information may be updated
and/or amended from time to time as circumstances change or more information becomes available.
Some of those revisions or changes may be material.
Each recipient of this Presentation should therefore perform their own independent analysis of the
business, operations, financial condition, creditworthiness, status and affairs of Enseval. Each recipient
should also conduct their own enquiries into the adequacy, accuracy, and completeness of any
information relating to Enseval, as the information and data contained in this Presentation are not
substitutes for the recipient’s independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.